Zhitong Finance App News, Haoyuan Pharmaceutical (688131.SH) announced that the company's wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd. (“Yaoyuan Qidong”), underwent pre-approval inspection from the US Food and Drug Administration (“FDA”) from June 22, 2026 to June 26, 2026. Recently, the company received an on-site inspection report issued by the US FDA forwarded by Yaoyuan Qidong. The report showed that Yaoyuan Qidong passed this on-site inspection with zero defects. This is the first time that the company's formulation production site has been inspected and successfully passed by the US FDA, providing a solid guarantee for the company to continue to expand the US market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.